Somatropin NICE approval extended

Somatropin (synthetic human growth hormone) can now be prescribed on the NHS for two additional paediatric indications.

In addition to children with growth failure associated with growth hormone deficiency, Turner syndrome, Prader-Willi syndrome or chronic renal insufficiency, somatropin is recommended as an option for children born small for their gestational age who experience subsequent growth failure at ≥4 years and those with short stature homeobox-containing gene (SHOX) deficiency.

NICE guidance states that treatment should be initiated, monitored and discontinued by a specialist.

Discontinuation is indicated if any of the following apply:

  • growth velocity increases less than 50% from baseline in the first year of treatment
  • final height is approached and growth velocity is less than 2cm in 1 year
  • there are insurmountable problems with adherence
  • final height is reached

Further information: NICE guidance on Somatropin

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more